Anti-Ro/SS-A antibodies are found in 35 to 60% of active and/or subacute systemic lupus erythematosus (SLE) and 60–70% of patients with primary Sjogren syndrome (SS)^{1, 2)}.

Anti-Ro/SS-A antibody in these diseases has been claimed to be involved in the pathogenesis of certain clinical features³⁾. However, the mechanism by which this antibody lead to tissue injury is unknown. Anti-Ro/SS-A antibodies have classically been identified by immunodiffusion in agarose gel. Using immunoprecipitation and immunoblot analysis, anti-Ro/SS-A antibodies were shown to target 60kDa and 52kDa Ro/SS-A proteins.

Previous studies in enzyme-linked immunosorbent assary (ELISA) and immunoblotting assay have described different patterns of anti-60kDa and anti-52kDa Ro responses between patients with primary SS and patients with SLE. In the present study, we evaluate the antibody responses of 60kDa and 52kDa Ro proteins and their clinical significances in Korean patients with primary SS.

Anti-Ro/SS-A autoantibodies are found in the sera of patients with SLE and SS. The percentages in differnet studies reported in the literature range from 38% to 96% in primary SS and from 12 to 69% in SLE^{6, 11)}. In the present study, using immunodiffusion, the frequency of anti-Ro antibody was 64.7% in primary SS patiens and 52.3% in SLE patients. The frequency of anti-Ro/SS-A antibodies in SS seen in our study may seem low but compares well with recent results reported by Chan et al¹²⁾. However, the prevalence of anti-Ro antibody in Korean patients with SLE was higher than that of Caucasian or Western countries^13–15). Ben-Chetrit et al. reported that prevalence of Ro/SSA antibody was 57% which is in keeping with the prevalence of this study. The prevalences of anti-Ro/SS-A antibodies in Korean patients with SLE were very similar to those of the Ben-Chetrit et al, but different from those of Maddison et al. (20%)¹⁵⁾. Pertinent to the reason of different prevalence are selection bias, different genetic background and detection methods including antigen extract. It has been demonstrated that occurrence of anti-Ro antibody are associated with certain HLA alleles although differences exist. Previous study reported that HLA DR3, which was linked to the occurrence of anti-Ro/SS-A antibody, was not common in oriental SLE including Korean^{16, 17)}. The relatively high prevalence of anti-Ro/SS-A in our SLE patients deserves further study to determine the possible involvement of genetic factors in the development of anti-Ro/SS-A antibody.

Anti-Ro positive sera contain two sets of antibody populations, directed to the 60kDa and the 52kDa polypeptide component of Ro proteins. It has been repoted that disease state influenced autoantigen recognition from the findings of different serum antibody responses to 60kDa and 52kDa Ro proteins in primary SS and SLE.

Simultaneous detection of antibodies to 60kDa and 52kDa was revealed by immunoblotting analysis with sera whose anti-Ro/SS-A antibody were positive by DID. The frequency of antibodies to 52kDa and 60kDa by immunoblot analysis was shown in Table 1. The prominent patterns associated with primary SS were antibodies to both the 60kDa and 52kDa Ro proteins and 52kDa Ro alone. Anti-52kDa Ro without anti-60kDa Ro antibody was a response that occured more commonly in primary SS than SLE sera. Our results also confirm the reports of Ben-Chetrit et al.⁴⁾ and Tsuzaka et al.²⁰⁾ that there are differences between primary SS and SLE in their immune responses to the Ro/SS-A proteins. Previous reports demonstrate that anti-52kDa without anti-60kDa antibody was found only in SS and was not detected in SLE^18–22). This difference might depend on the method that detects Ro/SS-A antigens. We definded anti-Ro/ SS-A antibodies by immunoblot, which detected antibodies to denatured Ro/SS-A antigens, while the report of Ben-Chetrit et al was performed by the immunoprecipitation method, in which Ro/SS-A antigen is native from.

Anti-SS-A/Ro antibodies have been demonstrated. to be related to subacute cutaneous lupus erythematosus, photosensitive rash, xerophthalmia and congenital heart block in patients with SLE, although controvery exists regarding the association of antibodies against Ro/SS-A antigen and particular features of SLE. In patients with SS, as shown in Fig. 1, anti-Ro/SS-A antibody positive group was correlated with the clinical mainfestations of cutaneous vasculitis, hyperglobulinemia, rheumatoid factor and anti-La/SS-B antibody positivity. These findings are similar to the reports of Alexander et al. and Harley et al.^{23, 24)}.

In the patients with anti-Ro/SS-A antibody positive sera, when we compare the clinically significant manifestations in SS patients with anti-Ro/SS-A antibodies and anti 60kDa and anti 52kDa antibody, we could not notice the difference between anti-52kDa antibody only positive group and both anti-60 and 52-kDa positive group which are the major determinants of anti-Ro antibodies. However, the number of patients with extraglandular manifestation observed in our study was not large enough to enable significant conclusions to be drawn.

In summary, the pattern of Ro/SS-A autoantigen recognition was different in SLE and primary SS. Anti-52kDa Ro without anti-60kDa Ro antibody was a response that occurred more commonly in primary SS than SLE, and served to distinguish the two disease entities. Although anti-Ro antibody was associated with the presence of some clinical manifestations in patients with primary SS, these findings were not correlated with the presence of antibodies against 60kDa or 52kDa protein. Additional studies are required to determine the exact correlation betwen antibodies against each peptides of 52kDa or 60kDa Ro/SS-A protein and certain clincial manifestations.